We are international
Donate
TEXT SIZE   

The International Myeloma Working Group, a collaborative group of leading myeloma specialists around the globe, has a two-fold task: to publish consensus statements and guidelines for the management of myeloma and to conduct translational research—from lab bench to patient bedside--under the auspices of the International Myeloma Foundation. The following publications represent both the work of the International Myeloma Working Group and the work of individual IMWG members who have based their papers on IMWG data sets that were made available to them.

Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
The prevalence of peripheral neuropathy (PNP) during the treatment of MM with Bortezomib is high.

About 20% of patients develop a grade 3-4 PNP due to this treatment, and as a result Bortezomib treatment is stopped or a reduced dose is given. Therefore, there is a strong need to find markers which predict the susceptibility of a patient to develop Bortezomib related PNP.

Click the PDF tab to view and dowload the document


Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma

The proteasome inhibitor bortezomib has demonstrated high antitumor activity in multiple myeloma (MM). Peripheral neuropathy (PNP) is a doselimiting toxicity of bortezomib, which typically occurs within the first cycles of bortezomib in 30-40% of MM patients. Although bortezomib induced PNP is manageable and reversible in most MM patients, no effective prophylactic treatment against PNP is available and bortezomib discontinuation is frequently required. Identifying patients at risk of neuropathy and understanding its pathogenesis is therefore of great importance.

Click on PDF tab to view and download the document


Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma

Multiple Myeloma (MM) is a plasma cell malignancy, characterized by significant heterogeneous disease progression and response to therapy. It is very likely that genetic polymorphisms of genes involved in drug absorption, distribution, metabolism and excretion may affect a patient’s response to therapy.

Click on the PDF tab to view and download the document.


Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma
Published in the Journal of Clinical Oncology, Volume 29, Number 7, March 1, 2011

Genetic Predisposition for Chemotherapy-Induced Neuropathy in Multiple Myeloma
Editorial
Published in the Journal of Clinical Oncology, Volume 29, Number 7, March 1, 2011

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations

It is anticipated that inherited single nucleotide polymorphisms (SNPs) in genes involved in drug absorption, distribution, metabolism and excretion influence individual response to thalidomide therapies in Multiple Myeloma. We extracted peripheral blood DNA from 631 myeloma patients of European descent enrolled in the MRC Myeloma IX trial who had received induction thalidomide (50-200mg). We genotyped 3404 SNPs selected in 983 candidate genes that may influence myeloma disease response, toxicity, and/or survival, on a “Bank on a Cure” (BOAC) Affymetrix® true-tag array.

Click on the PDF tab to view and download the document


Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival

We have engaged in an international program designated the Bank On A Cure, which has established DNA banks from multiple cooperative and institutional clinical trials, and a platform for examining the association of genetic variations with disease risk and outcomes in multiple myeloma.

Click on the PDF tab to view and download the document


Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Published in Lancet Oncol 2010; 11: 1057–65